Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900978 | 1.00 | LOXL2 (0.43) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL14448531 | 1.00 | LOXL2 (0.43) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL391675 | 0.84 | LOXL2 (0.41) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL391676 | 0.84 | LOXL2 (0.41) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL1444985 | 0.82 | ANPEP (0.41) | KDM4E | |
| SCHEMBL15157661 | 0.79 | SLC6A4 (0.52) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL14980656 | 0.79 | ANPEP (0.48) | LOXL2CA2CA12CA3CA6 | |
| Hydrochloric Acid SCHEMBL28699275 | 0.79 | LOXL2 (0.48) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL13813062 | 0.78 | CA12 (0.46) | LOXL2CA2CA12CA3CA6 | |
| Hydrochloric Acid SCHEMBL7649730 | 0.78 | LOXL2 (0.42) | LOXL2CA2CA12CA3CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-08-05 | — | — | US | disclosed |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3527569-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA FOR USE IN TREATING DRYE EYE | Vitae Pharmaceuticals, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3102576-B1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20170260180-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-09-14 | — | — | US | disclosed |
| US-20170260180-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-09-14 | — | — | US | disclosed |
| US-9624217-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9266886-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266886-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| CN-103228649-B | Quinazoline methane amide azetidine | MERCK PATENT GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| WO-2015116904-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2643313-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | Merck Patent GmbH (DE) | 2013-10-02 | — | — | EP | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | LOXL2 4083/4885CA2 1302/4885CA12 3438/4885 |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | LOXL2 3899/4885CA2 1037/4885CA12 2908/4885 |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | LOXL2 4083/4885CA2 1302/4885CA12 3438/4885 |
| US-20170260180-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | LOXL2 4083/4885CA2 1302/4885CA12 3438/4885 |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | LOXL2 4083/4885CA2 1302/4885CA12 3438/4885 |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | AZI2, NQO2, ABL1 | LOXL2 4350/4885CA2 2757/4885CA12 3730/4885 |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | LOXL2 4083/4885CA2 1302/4885CA12 3438/4885 |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | LOXL2 4083/4885CA2 1302/4885CA12 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.